Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.

Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary. Gynecol Oncol. 2025 Dec; 203:158-164.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Carcinosarcoma
Feasibility Studies
Female
Humans
Middle Aged
Neoplasm Recurrence, Local
Ovarian Neoplasms
Paclitaxel
Pyrazoles
Quinolines
Uterine Neoplasms

authors with profiles

Laura L Holman
Kai Ding
Christina Renay Washington
Deepika Neelakantan
Robert S Mannel
Debra L Richardson
Shailendra Kumar Dhar Dwivedi
Resham Bhattacharya